CN117098558A - 聚噁唑啉-脂质缀合物及包含其的脂质纳米颗粒和药物组合物 - Google Patents
聚噁唑啉-脂质缀合物及包含其的脂质纳米颗粒和药物组合物 Download PDFInfo
- Publication number
- CN117098558A CN117098558A CN202280026034.0A CN202280026034A CN117098558A CN 117098558 A CN117098558 A CN 117098558A CN 202280026034 A CN202280026034 A CN 202280026034A CN 117098558 A CN117098558 A CN 117098558A
- Authority
- CN
- China
- Prior art keywords
- lipid
- compound
- poz
- group
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nanotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163147470P | 2021-02-09 | 2021-02-09 | |
| US63/147470 | 2021-02-09 | ||
| PCT/US2022/015314 WO2022173667A1 (en) | 2021-02-09 | 2022-02-04 | Polyoxazoline-lipid conjugates and lipid nanoparticles and pharmaceutical compositions including same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117098558A true CN117098558A (zh) | 2023-11-21 |
Family
ID=82703446
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280026034.0A Pending CN117098558A (zh) | 2021-02-09 | 2022-02-04 | 聚噁唑啉-脂质缀合物及包含其的脂质纳米颗粒和药物组合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12233132B2 (https=) |
| EP (1) | EP4291242A4 (https=) |
| JP (1) | JP2024505723A (https=) |
| KR (1) | KR20230144574A (https=) |
| CN (1) | CN117098558A (https=) |
| AU (1) | AU2022219902A1 (https=) |
| CA (1) | CA3206128A1 (https=) |
| IL (1) | IL304773A (https=) |
| WO (1) | WO2022173667A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023031392A2 (en) | 2021-09-03 | 2023-03-09 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine |
| MX2024002726A (es) | 2021-09-03 | 2024-03-20 | CureVac SE | Nuevas nanoparticulas lipidicas para la administracion de acidos nucleicos. |
| WO2023073228A1 (en) | 2021-10-29 | 2023-05-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
| US20250099614A1 (en) | 2022-01-28 | 2025-03-27 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
| CN118900701A (zh) * | 2022-01-31 | 2024-11-05 | 盖纳万科学有限公司 | 聚(烷基噁唑啉)-脂质缀合物及含有聚(烷基噁唑啉)-脂质缀合物的脂质颗粒 |
| AU2023425729A1 (en) * | 2023-01-20 | 2025-07-17 | Serina Therapeutics (Al), Inc. | Targeting of antigen-presenting cells by nanoparticles containing polyoxazoline-lipid conjugates |
| KR20250153298A (ko) | 2023-03-08 | 2025-10-24 | 큐어백 에스이 | 핵산 전달을 위한 신규의 지질 나노입자 제형 |
| WO2024192291A1 (en) | 2023-03-15 | 2024-09-19 | Renagade Therapeutics Management Inc. | Delivery of gene editing systems and methods of use thereof |
| EP4680595A2 (en) | 2023-03-15 | 2026-01-21 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2024230934A1 (en) | 2023-05-11 | 2024-11-14 | CureVac SE | Therapeutic nucleic acid for the treatment of ophthalmic diseases |
| IL324725A (en) * | 2023-06-15 | 2026-01-01 | Serina Therapeutics Al Inc | Poly(oxazoline) conjugates with pendant cationic groups and lipid nanoparticles and polyplexes comprising them |
| WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025137256A1 (en) * | 2023-12-20 | 2025-06-26 | Wu Nian | Polyoxazoline-carbohydrate-lipid conjugates |
| WO2025134071A1 (en) | 2023-12-22 | 2025-06-26 | Sanofi | Malic and glutaric acid based ionizable lipids |
| WO2025155753A2 (en) | 2024-01-17 | 2025-07-24 | Renagade Therapeutics Management Inc. | Improved gene editing system, guides, and methods |
| WO2025174765A1 (en) | 2024-02-12 | 2025-08-21 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025196065A1 (en) | 2024-03-20 | 2025-09-25 | Sanofi | Novel homocysteine based lipids and their use for delivery of nucleic acids |
| WO2025257084A1 (en) * | 2024-06-10 | 2025-12-18 | Isar Bioscience Gmbh | Lipid composition |
| WO2026008743A1 (en) | 2024-07-02 | 2026-01-08 | Sanofi Pasteur Inc. | Water-soluble polyanionic polymer as adjuvant for carrier-formulated nucleic acid |
| WO2026053147A1 (en) | 2024-09-05 | 2026-03-12 | Sanofi Pasteur Inc. | Helper lipids and lnp compositions comprising same |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| JP2602544B2 (ja) * | 1989-03-20 | 1997-04-23 | 花王株式会社 | 新規オリゴマー、その製法および用途 |
| US5395619A (en) * | 1993-03-03 | 1995-03-07 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
| JPH08286313A (ja) * | 1995-04-14 | 1996-11-01 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料 |
| US20020001614A1 (en) * | 2000-02-10 | 2002-01-03 | Kent Jorgensen | Lipid-based drug delivery systems containing phospholipase A2 degradable lipid derivatives and the therapeutic uses thereof |
| KR101508621B1 (ko) | 2007-02-28 | 2015-04-07 | 세리나 쎄라퓨틱스, 인코포레이티드 | 활성화된 폴리옥사졸린 및 이를 포함하는 조성물 |
| US8088884B2 (en) | 2007-09-27 | 2012-01-03 | Serina Therapeutics, Inc. | Multi-armed forms of activated polyoxazoline and methods of synthesis thereof |
| US8110651B2 (en) | 2008-01-11 | 2012-02-07 | Serina Therapeutics, Inc. | Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same |
| US8101706B2 (en) | 2008-01-11 | 2012-01-24 | Serina Therapeutics, Inc. | Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same |
| JP5642673B2 (ja) * | 2008-07-10 | 2014-12-17 | セリナ・セラピユーテイツクス・インコーポレーテツド | 不活性末端基を有するポリオキサゾリン類、保護された開始基から調製されるポリオキサゾリン類及び関連化合物 |
| US20110313017A1 (en) * | 2010-01-13 | 2011-12-22 | Protiva Biotherapeutics, Inc. | Snalp formulations containing polyoxazoline-dialkyloxypropyl conjugates |
| SG186085A1 (en) * | 2010-06-03 | 2013-01-30 | Alnylam Pharmaceuticals Inc | Biodegradable lipids for the delivery of active agents |
| PT3970742T (pt) * | 2010-08-31 | 2022-06-27 | Glaxosmithkline Biologicals Sa | Lipossomas peguilados para entrega de arn codificador de imunogénio |
| US8383093B1 (en) | 2011-11-01 | 2013-02-26 | Serina Therapeutics, Inc. | Subcutaneous delivery of poly(oxazoline) conjugates |
| US12485181B2 (en) * | 2019-06-28 | 2025-12-02 | Serina Therapeutics (Al), Inc. | Polyoxazoline-drug conjugates with novel pharmacokinetic properties |
-
2022
- 2022-02-04 CN CN202280026034.0A patent/CN117098558A/zh active Pending
- 2022-02-04 CA CA3206128A patent/CA3206128A1/en active Pending
- 2022-02-04 US US17/665,190 patent/US12233132B2/en active Active
- 2022-02-04 JP JP2023547812A patent/JP2024505723A/ja active Pending
- 2022-02-04 WO PCT/US2022/015314 patent/WO2022173667A1/en not_active Ceased
- 2022-02-04 KR KR1020237030341A patent/KR20230144574A/ko active Pending
- 2022-02-04 AU AU2022219902A patent/AU2022219902A1/en active Pending
- 2022-02-04 EP EP22753169.6A patent/EP4291242A4/en active Pending
-
2023
- 2023-07-26 IL IL304773A patent/IL304773A/en unknown
- 2023-11-07 US US18/387,528 patent/US20240108750A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3206128A1 (en) | 2022-08-18 |
| EP4291242A4 (en) | 2025-11-26 |
| AU2022219902A1 (en) | 2023-08-10 |
| US20240108750A1 (en) | 2024-04-04 |
| US12233132B2 (en) | 2025-02-25 |
| EP4291242A1 (en) | 2023-12-20 |
| JP2024505723A (ja) | 2024-02-07 |
| WO2022173667A1 (en) | 2022-08-18 |
| KR20230144574A (ko) | 2023-10-16 |
| IL304773A (en) | 2023-09-01 |
| US20220249695A1 (en) | 2022-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN117098558A (zh) | 聚噁唑啉-脂质缀合物及包含其的脂质纳米颗粒和药物组合物 | |
| Umar et al. | Liposome-polymer complex for drug delivery system and vaccine stabilization | |
| JP7202009B2 (ja) | ｓｉＲＮＡ細胞内送達のための脂質膜構造体 | |
| JP2003520210A (ja) | 低い水溶性を有する薬物の送達のための薬学的処方物 | |
| US20240384277A1 (en) | Engineered polynucleotides for cell-type or microenvironment-specific expression | |
| WO2024160829A1 (en) | Compositions and methods | |
| Wang et al. | Bivalent mRNA vaccines against three SARS-CoV-2 variants mediated by new ionizable lipid nanoparticles | |
| US20250387334A1 (en) | Oxyanion azide-benzaldehyde acetal acid-degradable lipids | |
| CN117500819A (zh) | 脂质和组合物 | |
| US20240315981A1 (en) | Sub-micron particle | |
| EP4709361A1 (en) | A compound for preparing lipid nanoparticles encapsulating an agent, nanoparticle composition comprising said compound and related methods thereof | |
| HK40103124A (zh) | 聚恶唑啉-脂质缀合物及包含其的脂质纳米颗粒和药物组合物 | |
| CN121152620A (zh) | 用含聚噁唑啉-脂质缀合物的纳米颗粒靶向抗原呈递细胞 | |
| JP7690222B2 (ja) | 動力学的制御が可能なアジュバントを含むｍＲＮＡワクチン | |
| KR20260026532A (ko) | 펜던트 양이온성 기를 갖는 폴리(옥사졸린) 접합체 및 이를 포함하는 지질 나노입자 및 폴리플렉스 | |
| TW202412818A (zh) | 用於暫時控制表現之經工程化多核苷酸 | |
| CN121135600A (zh) | 可电离脂质化合物及其应用 | |
| Hartikainen | RECENT PROGRESS ON SPHERICAL NUCLEIC ACID-BASED DRUG DELIVERY SYSTEMS | |
| EP4658250A1 (en) | Compositions and methods | |
| CN117203186A (zh) | 一种含有二硫键的脂质化合物及其组合物 | |
| HK40096911A (zh) | 脂质化合物和脂质纳米颗粒组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Country or region after: U.S.A. Address after: alabama Applicant after: Serena Treatment Alabama Co. Address before: alabama Applicant before: Serina Therapeutics, Inc. Country or region before: U.S.A. |